March 17, 2005 |
Citing a desire to avoid an "undue burden on employees," the National Institutes of Health is exempting its temporary researchers from a pending requirement to divest stock holdings in biomedical companies. The agency this week also told permanent staff researchers that they had an additional six months -- until early October -- to dispose of such holdings. The adjustments to the NIH's new and more restrictive conflict-of-interest policy were announced in an internal memo by Dr. Raynard S.
March 3, 2005 |
When a group of senior government scientists announced their opposition to new and restrictive conflict-of-interest rules at the National Institutes of Health last week, they complained that the agency's mission was in danger of being irreparably compromised. They said the new rules, which ban NIH employees from accepting consulting fees or stock options from biomedical companies, would victimize even food handlers and elevator operators.
February 12, 2005 |
The director of the National Institutes of Health -- describing consulting payments from drug companies as a "systemic problem" that threatened the integrity of his agency -- has called for a summit of government and academic leaders to address conflicts of interest throughout American medical research. Dr. Elias A. Zerhouni last week banned all of his agency's scientists from accepting consulting fees, stock or any other compensation from the biomedical industry.
February 2, 2005 |
The director of the National Institutes of Health, Dr. Elias A. Zerhouni, said that rules he announced Tuesday banning all staff scientists from taking drug-company fees would help the federal research agency set the highest ethical example. Referring to the pervasive intermingling of pharmaceutical marketing with medical research nationally, Zerhouni said the time had come for the NIH to provide "at least one source of public health information in the country that can be completely trusted."
February 1, 2005 |
Under a far-reaching reform to be announced today, all staff scientists at the National Institutes of Health will be banned from accepting any consulting fees or other income from drug companies, and the employees must also divest industry stock holdings, officials said.
January 28, 2005 |
Ethics specialists at the National Institutes of Health have requested an outside investigation of an Alzheimer's disease researcher who accepted more than $500,000 from a drug company without seeking permission or reporting the income to the agency as required, according to government officials familiar with the matter. In response, the investigations unit of the inspector general's office at the Department of Health and Human Services has opened an inquiry into the researcher, Dr. P.
December 22, 2004 |
For 15 million Americans, it is a daily ritual: gulping down a pill to reduce cholesterol. They do it because their doctors tell them to. Their doctors, in turn, rely on recommendations from the National Institutes of Health and its scientists, such as Dr. H. Bryan Brewer Jr. Brewer, as a leader at the NIH, was part of a team that gave the nation new cholesterol guidelines that were expected to prompt millions more people to take the daily pill.
September 24, 2004 |
The director of the National Institutes of Health has decided to ban all agency employees from accepting consulting payments from drug companies for at least one year, officials said Thursday. The move is the latest and potentially most far reaching response by NIH director Elias A. Zerhouni to revelations of multiple conflicts of interest among agency scientists. In July, a report by the U.S.
May 19, 2004 |
The director of the National Institutes of Health is requiring agency employees to report the financial details of any consulting payments received from drug companies over the last five years or face dismissal, a spokesman said Tuesday. The edict from the NIH director, Dr. Elias A. Zerhouni, comes as the agency is facing increased pressure from congressional leaders to rescind policies and practices that have fostered potential conflicts of interest involving agency scientists.